≡

Mouse Model for Allergic Encephalomyelitis (AE)

Experimental allergic encephalomyelitis, EAE

  • Product No.DSI694Mu01
  • Organism SpeciesMus musculus (Mouse) Same name, Different species.
  • Prototype SpeciesHuman
  • SourceInduced by Injection of MOG35~55 peptide
  • Model Animal StrainsC57BL/6 Mice(SPF), healthy, male, age: 4~6 weeks, body weight:18g~20g.
  • Modeling GroupingRandomly divided into six group: Control group, Model group, Positive drug group and Test drug group.
  • Modeling Period4-6 weeks
  • Modeling MethodMultiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system with high rates of relapse, persistence and disability. It is difficult to obtain MS specimens, which limits the research on this disease. Therefore, establishing the corresponding animal model is an important way to study the pathological process and pathogenesis of MS.
    Model induced MICE in EAE group: the antigen myelin oligodectin glycoprotein (MOG35-55) polypeptide was diluted to 300ug/50ul, and the same amount of complete Adjuvant was added at the rate of 1:1. After full emulsification, the mice were injected subcutaneously at the rate of 100ul per mouse in axilla. On the day of immunization and 24h after immunization, mice were injected 100ul PBS containing 200ng pertussis toxin through tail vein. PBS control group was induced with PBS instead of antigen, same as EAE group.
  • ApplicationsUsed for therapeutic effect research and immunological mechanism of drugs on mice with autoimmune encephalomyelitis
  • Downloadn/a
  • UOM Each case
  • FOB US$ 200 
    For more details, please contact local distributors!

Model Evaluation

1. Neurological function score:
The body weight of the mice was measured from the day of immune induction, and the neurological function was scored by double-blind method 32 days after immunization. The specific scoring criteria were as follows:
Level 0, no clinical manifestation;
Level 1, spiritually depressed, tail weak;
Level 2, walking gait abnormality, double leg weakness;
Level 3, double paralyzed hind legs;
Level 4, the double either one or both hind legs paralyzed with forelimbs collapse;
Level 5, near death or dead. Recurrence was defined as a recurrence with a higher clinical score than before after recovery from the initial episode, or the same score continued for more than 3 days.
2. Clinical manifestations
Acute onset in mice was induced at 12±3 days, peaked within 16±2 days, and then gradually recovered to mild weakness or stiffness in the tail. The severity score of the onset in mice was 3.2±0.6.

Pathological Results

Tissue sampling and pathological analysis At the peak of EAE model, the mice were anesthetized by intraperitoneal injection of chloral hydrate, and their brain and spinal cord were taken, fixed in 4% paraformaldehyde, embedded in paraffin, and observed by HE and solid green staining.
There were inflammatory cell infiltrates in the parenchyma of both brain and spinal cord, but the distribution of the lesions was mainly cervical and lumbar enlargement of the spinal cord, which was characterized by a large number of lymphocytes and neutrophils. The infiltrates extended from outside to inside along the capsule and small blood vessels, and vascular sheath formation was observed around small blood vessels. Solid green staining showed that there were lamellar myelin demyelination areas of different sizes in the inflammatory infiltrated areas of the spinal cord white matter, and myelin fibers were loose and a large number of vacuolates were formed. There were no obvious abnormal changes in brain and spinal cord in PBS control group and normal control group.

Cytokines Level

Statistical Analysis

SPSS software is used for statistical analysis, measurement data to mean ± standard deviation (x ±ｓ), using t test and single factor analysis of variance for group comparison, P<0.05 indicates there was a significant difference, P<0.01 indicates there are very significant differences.

GIVEAWAYS

INCREMENT SERVICES

Catalog No. Related products for research use of Mus musculus (Mouse) Organism species Applications (RESEARCH USE ONLY!)
DSI694Mu01 Mouse Model for Allergic Encephalomyelitis (AE) Used for therapeutic effect research and immunological mechanism of drugs on mice with autoimmune encephalomyelitis
DSI694Mu02 Mouse Model for Allergic Encephalomyelitis (AE) n/a